This article is more than 5 years old. Information may no longer be current.

FDA grants priority review to rociletinib for advanced NSCLC

The FDA granted priority review to a new drug application for rociletinib.

Rociletinib (Clovis Oncology) — a novel, oral, targeted covalent mutant-selective epidermal growth factor receptor inhibitor — is intended for patients with advanced EGFR-mutant, T790M-positive non–small cell lung cancer who already received EGFR-targeted therapy.

The FDA is expected to make a decision about the agent’s status by March 30, 2016.

The agency based its priority review designation on results of the single-arm TIGER-X and TIGER-2 clinical trials, which evaluated rociletinib in patients with advanced EGFR-mutant NSCLC whose tumors harbor a T790M mutation.

The FDA granted breakthrough therapy designation to rociletinib in May 2014.